Operating Expenses
Acquired in-process research and development
Regeneron Pharmaceuticals Acquired in-process research and development increased by 444.9% to $101.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 728.5%, from $12.30M to $101.90M. Over 4 years (FY 2021 to FY 2025), Acquired in-process research and development shows an upward trend with a 26.8% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2020
Last reportedQ1 2026Apr 29, 2026
How to read this metric
An increase signals an active inorganic growth strategy, while a decrease suggests a reliance on internal R&D or a pause in M&A activity.
Detailed definition
This metric captures the costs associated with acquiring research and development projects from third parties that have...
Peer comparison
Common in the biotech industry as companies frequently acquire smaller firms to fill pipeline gaps.
Metric ID:
operating_expenses_acquired_in_process_research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $48.00M | $28.10M | $197.00M | $0.00 | $30.00M | $56.10M | $0.00 | $100.00M | $30.00M | $7.10M | $23.90M | $56.20M | $13.80M | $12.30M | $10.00M | $83.10M | $18.70M | $101.90M |
| QoQ Change | — | — | — | -41.5% | +601.1% | -100.0% | — | +87.0% | -100.0% | — | -70.0% | -76.3% | +236.6% | +135.1% | -75.4% | -10.9% | -18.7% | +731.0% | -77.5% | +444.9% |
| YoY Change | — | — | — | — | — | — | -37.5% | +99.6% | -100.0% | — | +0.0% | -87.3% | — | -43.8% | -54.0% | +73.2% | -58.2% | +47.9% | +35.5% | +728.5% |
Range$0.00 – $197.00M
Avg YoY Growth+50.3%
Median YoY Growth-18.8%
Acquired in-process research and development at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's acquired in-process research and development?
- Regeneron Pharmaceuticals (REGN) reported acquired in-process research and development of $101.90M in Q1 2026.
- How has Regeneron Pharmaceuticals's acquired in-process research and development changed year-over-year?
- Regeneron Pharmaceuticals's acquired in-process research and development increased by 728.5% year-over-year, from $12.30M to $101.90M.
- What is the long-term trend for Regeneron Pharmaceuticals's acquired in-process research and development?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's acquired in-process research and development has grown at a 26.8% compound annual growth rate (CAGR), from $48.00M to $124.10M.
- What does acquired in-process research and development mean?
- Costs incurred to purchase ongoing research projects from other companies.